MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Lee, Chih Shia ^a,b   Dykema, Karl J ^a   Hawkins, Danielle M ^a   Cherba, David M ^a   Webb, Craig P ^a   Furge, Kyle A ^a   Duesbery, Nicholas S ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; COMPLEMENTARY DNA; LEUCINE; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHENYLALANINE; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; MAP2K2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; ANIMAL; CANCER INVASION; CELL ADHESION; CHO CELL; CLUSTER ANALYSIS; CRICETULUS; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; GENE EXPRESSION PROFILING; GENETICS; HAMSTER; MELANOMA; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CATALYTIC DOMAIN; CELL ADHESION; CELL PROLIFERATION; CHO CELLS; CLUSTER ANALYSIS; CRICETINAE; CRICETULUS; GENE EXPRESSION PROFILING; HUMANS; MAP KINASE KINASE 2; MELANOMA; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; POINT MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79951968708     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017165     Document Type: Article

References (52)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
2. Tsao H, Zhang X, Fowlkes K, Haluska FG, (2000) Relative Reciprocity of NRAS and PTEN/MMAC1 Alterations in Cutaneous Melanoma Cell Lines. Cancer Res 60: 1800-1804.
3. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, et al. (2002) Mitogen-actived Protein Kinase Activation Is an Early Event in Melanoma Progression. Clin Cancer Res 8: 3728-3733.
4. Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, et al. (2003) Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling. J Biol Chem 278: 9790-9795.
5. Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, et al. (2004) Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23: 8796.
6. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, et al. (2004) V599EB-RAF is an Oncogene in Melanocytes. Cancer Res 64: 2338-2342.
7. Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo D, (2005) Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma Cells. Mol Biol Cell 16: 4153-4162.
8. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS, (2003) Treatment of Metastatic Melanoma with an Orally Available Inhibitor of the Ras-Raf-MAPK Cascade. Cancer Res 63: 5669-5673.
9. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358.
10. Koo H-M, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, et al. (2002) Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United States of America 99: 3052-3057.
11. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, et al. (2005) BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 4: 1303-1310.
12. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
13. Lee CS, Duesbery NS, (2010) Highly Selective MEK inhibitors. Current Enzyme Inhibition In press.
14. LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, et al. (2005) Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies. J Clin Oncol 23: 5281-5293.
15. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581-586.
16. Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, et al. (2007) Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell 12: 615-629.
17. Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, et al. (1999) Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Current Biology 9: 369.
18. Belanger L-F, Roy S, Tremblay M, Brott B, Steff A-M, et al. (2003) Mek2 Is Dispensable for Mouse Growth and Development. Mol Cell Biol 23: 4778-4787.
19. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, et al. (2008) Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 8: 337.
20. Scholl FA, Dumesic PA, Barragan DI, Harada K, Charron J, et al. (2009) Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia. Cancer Res 69: 3772-3778.
21. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME, (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
22. MacKeigan JP, Collins TS, Ting JP, (2000) MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275: 38953-38956.
23. Estrada Y, Dong J, Ossowski L, (2009) Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res 22: 66-76.
24. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. (1998) Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor. Science 280: 734-737.
25. Singh Y, Liang X, Duesbery NS, (2005) Pathogenesis of Bacillus anthracis: the role of Anthrax toxins. In: Proft T, editors. Microbial Toxins Molecular and Cellular Biology Norfolk, England Horizon Bioscience pp. 285-312.
26. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C, (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462: 199-204.
27. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C, (2000) Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J 352: 739-745.
28. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, et al. (1998) Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured Macrophages. Biochemical and Biophysical Research Communications 248: 706-711.
29. Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, et al. (2001) Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proceedings of the National Academy of Sciences of the United States of America 98: 4089-4094.
30. Tanoue T, Adachi M, Moriguchi T, Nishida E, (2000) A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2: 110-116.
31. Chopra AP, Boone SA, Liang X, Duesbery NS, (2003) Anthrax Lethal Factor Proteolysis and Inactivation of MAPK Kinase. J Biol Chem 278: 9402-9406.
32. Bardwell AJ, Abdollahi M, Bardwell L, (2004) Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. Biochem J 378: 569-577.
33. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
34. Park JM, Greten FR, Li Z-W, Karin M, (2002) Macrophage Apoptosis by Anthrax Lethal Factor Through p38 MAP Kinase Inhibition. Science 297: 2048-2051.
35. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, et al. (2007) Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 67: 3171-3176.
36. Furge KA, Tan MH, Dykema K, Kort E, Stadler W, et al. (2007) Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene 26: 1346-1350.
37. Davis RJ, (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
38. Roux PP, Blenis J, (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
39. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, et al. (2001) MAP kinases. Chem Rev 101: 2449-2476.
40. Johnson GL, Lapadat R, (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912.
41. Chang L, Karin M, (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
42. Scholl FA, Dumesic PA, Barragan DI, Charron J, Khavari PA, (2009) Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin. Oncogene 28: 1485-1495.
43. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA, (2001) Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
44. Scobie HM, Rainey GJ, Bradley KA, Young JA, (2003) Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A 100: 5170-5174.
45. Tasaki T, Kwon YT, (2007) The mammalian N-end rule pathway: new insights into its components and physiological roles. Trends Biochem Sci 32: 520-528.
46. Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, et al. (2008) Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 7: 648-658.
47. Mansour SJ, Resing KA, Candi JM, Hermann AS, Gloor JW, et al. (1994) Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem 116: 304-314.
48. Bromberg-White JL, Duesbery NS, (2008) Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways. Methods Enzymol 438: 355-365.
49. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
50. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, et al. (2006) Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol 24: 1140-1150.
51. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
52. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.